IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA SUBSIDIARY LISTING
� JAPAN
AMATO
Full Name: Amato Phar ma ceu ti cal Prod ucts Ltd
Street Ad dress: 995 Sasao-cho,
Fukuchiyama-shi, Kyoto 620-0932
Tel: +81 77 322 1100
Fax: +81 77 323 3355
Sub sid iary of: Takeda, Ja pan (30%)
Phar ma ceu ti cal Sales: US$ 70-75 mil lion
Prod ucts (% of Sales by Lead ing 5):
95-100%
Ther a peu tic Classes (% of Sales by Lead ing
5): n.a.
Dose Forms (% of Sales by Lead ing 5): n.a.
Prin ci pal Prod ucts:
BORRAGINOL (antihemorrhoidal top i cal; var i cose
ther apy sys temic)
BORRAZA G (antihemorrhoidal top i cal)
HEMOCURON (var i cose ther apy sys temic)
Ther a peu tic Range:
antivaricosis/antihemorrhoidal prep a ra tions
100%
Lead ing Dose Forms:
oint ments 64%
sup pos i to ries 32%
cap sules 3%
pow ders/gran ules 2%
NIHON PHARMACEUTICALS
Full Name: Nihon Phar ma ceu ti cal Co. Ltd.
Street Ad dress: 9-8, Higashikanda 1-chome,
Chiyoda-ku, To kyo 101-0031
Tel: +81 3 3864 8411
Fax: +81 3 5687 9485
Home Page: www.nihon-pharm.co.jp
Sub sid iary of: Takeda, Ja pan (87.5%)
Phar ma ceu ti cal Sales: US$ 140-150 mil lion
Prod ucts (% of Sales by Lead ing 5): 80-85%
Ther a peu tic Classes (% of Sales by Lead ing
5): 85-90%
Dose Forms (% of Sales by Lead ing 5):
95-100%
Prin ci pal Prod ucts:
GLOVENIN I (im mu no glob u lin G IV)
NONTHRON KENKETU (proteinase in hib i tor)
AL BU MIN NICHIYAKU (pro tein so lu tion)
ALBUMINATE NICHIYA (pro tein so lu tion)
OSVAN (an ti sep tic/dis in fec tant)
Ther a peu tic Range:
sera/gammaglobulins 51%
antihemorrhagics 16%
blood/plasma sub sti tutes 12%
IV so lu tions over 100cc 6%
an ti sep tics and dis in fec tants 4%
Lead ing Dose Forms:
vi als 79%
in fu sions 11%
pow ders/gran ules 4%
liq uids 4%
tab lets 2%
TAKEDA
Full Name: Takeda Phar ma ceu ti cal Com pany
Lim ited
Street Ad dress: 1-1 Doshomachi 4-chome,
Chuo-ku, Osaka 540-8645
Tel: +81 6 6204 2111
Fax: +81 6 6204 2880
Home Page: www.takeda.co.jp
De scrip tion: Man u fac turer, re searcher, de vel -
oper, im porter, ex porter, dis trib u tor, pro moter.
De vel ops, dis trib utes for other com pa nies. Prod -
uct ranges in clude: phar ma ceu ti cal prod ucts
(branded, pre scrip tion, non-pre scrip tion), in ter -
me di ates, di ag nos tic prod ucts, med i cal equip -
ment, vet er i nary pharmaceuticals. Es tab lished
1925. 14,993 phar ma ceu ti cal em ploy ees in 2007.
Di vi sions in clude: Pharmaceuticals; Vitamin &
Food (bulk vitamins); Chemical Products.
Con tacts (Pharm): Chair man: Yasuchika
Hasegawa; Com mer cial Op er a tions: Makoto
Yamaoka; Man u fac ture: Akira Nakatani; Re -
search & De vel op ment: Dr Shigenori Ohkawa
(Phar ma ceu ti cal Re search), Dr Masaomi
Miyamoto (Phar ma ceu ti cal De vel op ment); Gen -
eral Contact: Takaharu Nishida
Par ent of: Tianjin Takeda, China (75%); Takeda,
In do ne sia (70%); Takeda, Ire land (100%);
Takeda Pharma, Ire land (100%); Amato, Ja pan
(30%); Nihon Pharmaceuticals, Ja pan (87.5%);
Wako Pure Chem i cal In dus tries, Ja pan (70.3%);
Takeda, Neth er lands (100%); Boie-Takeda, Phil -
ip pines (50%); Green Cross, Sin ga pore (12%);
Takeda, Tai wan (100%); Takeda, Thai land
(48%); Par a digm Ther a peu tics, UK; Mil len nium,
USA (100%) (ac quired 2008); Takeda Amer ica
Holdings, USA (100%).
Phar ma ceu ti cal Sales: US$ 4,200-4,300 mil -
lion
Prod ucts (% of Sales by Lead ing 5): 70-75%
Ther a peu tic Classes (% of Sales by Lead ing
5): 75-80%
Dose Forms (% of Sales by Lead ing 5):
95-100%
© 2009 IMS Health In cor po rated or its af fil i ates Page 126